TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens ...
At Tersigni Vision, a growing number of patients are asking whether Refractive Lens Exchange (RLE)—also known as Custom Lens Replacement—can correct astigmatism and reduce their dependence on glasses ...
In amblyopia, the brain and the affected eye do not work together properly. The brain begins to favour the stronger eye and gradually ignores signals from the weaker one.
The qCXL platform employs a customised treatment planning engine and real-time ultrasound monitoring for precision.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results